
    
      Primary endpoint: Composite of Major Adverse Cardiac Events (MACE), which includes cardiac
      death, myocardial infarction (Q-wave and non Q-wave) and clinically driven target lesion
      revascularization (TLR) at 12 months follow-up.

      Data will be collected on 400 patients (from 14 hospitals in Spain and Portugal) treated with
      the Presillion stent in up to 2 de novo native coronary artery lesions

      Study design: multicenter, prospective, observational
    
  